55 results about "Hepatic metastasis" patented technology

The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as well as conjugates and formulations of such peptides for diagnostic and therapeutic purposes.

The invention provides long noncoding RNA (ribonucleic acid) CLMAT1 related with colorectal liver metastasis and application of the long noncoding RNA CLAMT1. The long noncoding RNA CLAMT1 is positioned at a 14th chromosome chr14: 101379770-101381326, hg19; the gene sequence length is 1557bp. Compared with normal intestinal tissues, intestinal tissues with the intestinal cancer has high expression of CLAMT1 which is positively correlated with liver metastases of colorectal cancer; in addition, bad prognosis of patients also indirectly prompts that the liver metastasis probability of the patients is relatively high.

The invention belongs to microbiological animal cell system fiels, which in detail relates to a pancreatic cancer hepatic metastases clone SW1990HM with hepatic metastases potence. The clone possesses special transition phenotype, and if inoculated to mouse spleen, it will result to 100% hepatic metastases, and it is the first human pancreatic cancer clone with hepatic metastases potence in domestic. The genetic backgroud of said clone strain is the same to that of origianl cell, and it is characterized by strong invasiveness, high transmission efficiency and large transmission range. The invention provides proper experimental platform for further researching, preventing and treating pancreatic cancer hepatic metastases.

The invention is based on the finding that in mammalian lungs c-myc acts as a molecular switch, specifically inducing an expression pattern in vivo, which results in prototypical mammalian adenocarcinoma of the lung and liver metastasis. A set of factors essential for the processes of tumorigenesis and tumor progression, i.e. cell cycle and apoptosis, cell growth, extracellular signaling, angiogenesis and invasion, is identified, whose expression is significantly changed. In particular, the expression pattern found uncovers the network of molecules leading to mammalian papillary adenocarcinomas of the lung.

The invention discloses an application of circular RNA WHSC1 in preparation of clinical diagnosis markers in colorectal cancer tumorigenesis and hepatic metastases diseases. The invention further discloses an application of the circular RNA WHSC1 serving as a therapeutic target of the colorectal cancer drug. The invention further discloses a preparation for treating colorectal cancer. The preparation comprises a sequence for specifically interfering the circular RNA WHSC1, wherein the sequence is used for inhibiting the level of the circular RNA WHSC1. Research results show clinical significances of the circ-WHSC1 in diagnosis of colorectal cancer and metastasis and an application in preparation of drugs for treating the colorectal cancer metastasis.

The invention provides a colorectal carcinoma cell line CJF from hepatic metastasis and a construction method thereof. The obtaining method of the colorectal carcinoma cell line comprises the following steps: obtaining tissues of colorectal carcinoma hepatic metastasis; after digesting the tissues into single cells by using collagenase / hyaluronidase, separating and inoculating CD133+ cells under NOD (Non-Obese Diabetic) / SCID rat skin by MACS (magnetic-activated cell separation); nodulating, and taking out tumor tissues; and culturing in vitro to obtain the colorectal carcinoma cell line CJF which can stably passage and is rich in colorectal carcinoma stem cells. In the invention, CJF cells are obtained from hepatic metastasis of colonic carcinoma patients; compared with other colorectal carcinoma cell lines, the colorectal carcinoma cell line CJF has incomparable advantages for the study of the colonic carcinoma hepatic metastases; cell subsets of the CJF cells for stably expressing the CD133+ cells is about 10 percent; and the action and the research of the colorectal carcinoma cell line in a colorectal carcinoma hepatic metastases process and the tumor stem cells in a metastases mechanism have wide application prospects.

The invention relates to a traditional Chinese medicinal composition for treating colon cancer hepatic metastases, which consists of the following raw material medicaments by weight: 3 to 9 grams of spreading hedyotis herb, 1,020 grams of golden thread, 20 to 40 grams of barbed skullcap herb, 20 to 40 grams of medlar, 5 to 20 grams of lightyellow sophora root, 5 to 20 grams of divaricate saposhnikovia root, 5 to 20 grams of bupleurum, 20 to 40 grams of swordlike atractylodes rhizome, 5 to 20 grams of large-headed atractylodes rhizome, 5 to 20 grams of dahurian patrinia herb, 20 to 40 grams of Indian iphigenia bulb, 20 to 40 grams of south dodder seed, 5 to 20 grams of black nightshade herb, 5 to 20 grams of ash bark, 20 to 40 grams of sargentodoxa stem, 20 to 40 grams of glossy privet fruit and 5 to 20 grams of amur corktree bark. The raw material medicaments are heated for extraction or diacolation in water or 30 to 90 percent ethanol, the material medicaments having been heated for the extraction or diacolation are purified to obtain extract, and then the extract is prepared into various preparations.

There is provided a method for inhibiting ATF / CREB and cancer cell growth using disulfiram, administered in combination with heavy metals. It was found that disulfiram disrupts transcription factor DNA binding by forming mixed disulfides with thiols within the DNA-binding region, and that this process is facilitated by metal ions. Disulfiram administered to melanoma cells in combination with copper (II) or zinc(II) decreased expression of cyclin A, reduced proliferation in vitro, and inhibited growth of melanoma cells. The combination of oral zinc gluconate and disulfiram at currently approved doses for alcoholism stabilized tumor growth in two of three patients with Stage IV metastatic melanoma, with 12 and 17 month survivals, respectively, to date, and produced a >50% reduction in hepatic metastases in one individual.

The invention discloses a colorectal cancer early hepatic metastasis animal model and a construction method and application thereof. Cell suspension concentration of the colorectal cancer early hepatic metastases animal model is 2.5*107 / ml, about 0.1ml of colorectal cancer cells are injected intrasplenically for 3min; a Vetbond 3M tissue adhesive is adopted for sealing an incision, and then the spleen is put back. The colorectal cancer early hepatic metastases animal model in different metastatic characteristics is constructed innovatively; differences of in-vitro nuclein uptake ratios of cancer cells in different metastatic potentials are verified; statistic differences of biological characteristic indexes of different cancer strains and metastatic nodules are found; early hepatic metastatic tumor development biological characteristics are reflected completely, and a novel method is provided for discovery and diagnosis of early hepatic metastasis.

The invention provides interfering RNA and a lentivirus vector targeted to the OLFM4 gene and application of the interfering RNA and the lentivirus vector in preparation of drugs used for preventing and treating metastasis of stomach cancer tumors to the abdominal cavity or / and the liver. According to the invention, since the interfering RNA can inhibit in vitro migration and invasion ability of gastric cancer cells and liver metastasis capability of gastric cancer cells, decreased expression of OLFM4 is a potential effective mode for treatment of malignant progression of late gastric cancer. It is further determined that an NF-kB signal is an upstream regulation transcription factor of expression of OLFM4 and the interfering RNA has NF-kB signal feeding back and regulating functions.

The invention relates to a methylation marker for intestinal cancer liver metastasis and application, and belongs to the technical field of molecular biomedicine. According to the method, intestinal cancer liver metastasis is researched through methylation of intestinal cancer for the first time, methylation difference related to liver metastasis of intestinal cancer is found to appear at the early stage of intestinal cancer for the first time, methylation difference sites of liver metastasis and non-liver metastasis of intestinal cancer are screened out, and five optimal difference methylation regions are used for screening methylation difference sites of liver metastasis and non-liver metastasis of intestinal cancer through a random forest method. And DMR) an intestinal cancer methylatedliver metastasis risk prediction model is established, which is suitable for predicting the risk assessment of liver metastasis of early intestinal cancer in the future.

The invention discloses an application of p.P476S mutation of a RBPJL gene as a PD-1 antibody medication guiding marker. Through infiltration research of a very special answer mode after a patient suffering from trachea squamous cell carcinoma accepts PD-1 antibody treatment, the inventor finds that a p.P476S mutant site of the RBPJL gene can influence the treatment effects on liver metastasis ofthe patient suffering from squamous cell carcinoma, so that when the p.P476S mutant site of the RBPJL gene is used as a marker for guiding the PD-1 antibody treatment, a PD-1 antibody treatment schemeof the patient suffering from trachea squamous cell carcinoma generating liver metastasis can be effectively guided, and the treatment effect of the patient can be substantially promoted. The p.P476Smutation disclosed by the invention has good application prospect and value.

The invention provides an application of an miR-10a-mediated tumor-associated fibroblast to a product with at least one of the following functions (1) to (6): (1) inhibiting tumor cell proliferation,(2) promoting tumor cell apoptosis, (3) inhibiting tumor cell migration, (4) inhibiting tumor cell invasion, (5) inhibiting tumor cell sphere formation, and (6) preventing and / or treating a tumor, wherein the tumor is a colorectal cancer; a tumor cell is a colorectal cancer cell; and a nucleotide sequence of miR-10a is as shown in SEQ ID NO:1. According to the application, the effect of the overexpressed miR-10a on liver fibroblast activity in vitro is known and understood from a new perspective, and the effect of a change of the liver fibroblast activity on formation of metastasis in liver bythe colorectal cancer cell is thoroughly discussed, so as to provide a molecular mechanism of hepatic metastasis in the colorectal cancer with an epigenetic basis and to provide a new idea and targetfor prevention and treatment of the colorectal cancer.

The invention discloses an in-vitro drug sensitivity detection device for drug resistance of the pancreatic cancer hepatic metastasis chemotherapy, and belongs to the technical field of in-vitro drug sensitivity detection devices. A culture dish is kept at the same and appropriate temperature through a constant-temperature assembly, a positioning lifting frame assembly is started, and a liquid guide pipe assembly is accurately aligned to the upper portion of the culture dish; then a corresponding electric adjusting assembly is started to drive a T-shaped piston rod assembly to operate, the T-shaped piston rod assembly is matched with a one-way valve assembly to guide liquid into a piston cavity firstly, then the T-shaped piston rod assembly is matched with a liquid guide pipe assembly to enable the liquid to flow into the culture dish for quantitative and accurate liquid adding, and meanwhile timing is conducted through a timer; and reminding is carried out when the measurement time is up.

The invention relates to screening and application of a urine protein marker related to liver metastatic cancer. Specifically, the present invention relates to a method for establishing an animal model for screening urine protein markers related to liver metastatic cancer. The invention also relates to application of the urine protein marker related to liver metastatic cancer obtained by the method in preparation of a kit for diagnosing liver metastatic cancer in a subject at an early stage. The urine protein marker is selected from one or more of parvalbumin alpha, annexin A1, a polymer immunoglobulin receptor, lysosome thioesterase (PPT2), cobalamin protein-2, a cathepsin H precursor, a galectin-3 binding protein, an HLA-I tissue compatible antigen, beta-2 microglobulin, vascular cell adhesion protein-1, complement C4, alpha-1-acid glycoprotein, or a combination thereof.

The invention discloses a traditional Chinese medicine recipe for treating liver cirrhosis and liver cancer postoperative or hepatic metastases tumor inhibition. The traditional Chinese medicine recipe is prepared from turtle shells, glossy ganoderma, radix astragali seu hedysari and caterpillar fungus. 500g of turtle shells subjected to clean washing and drying in the shade are stir-fried to be slightly yellow by yellow sand; the sand is removed, and the turtle shells are left; the turtle shells leave away from the fire; 50 to 100g of white vinegar is used for uniform spraying when the turtle shells are still hot; stewing and drying in the shade are performed; roasted turtle shells are prepared; the roasted turtle shells, the glossy ganoderma, the radix astragali seu hedysari and the caterpillar fungus are ground into powder and are mixed to obtain a finished product. Compared with the prior art, the traditional Chinese medicine recipe is prepared from pure traditional Chinese medicine, and can be used for treating the liver cirrhosis, liver cancer or hepatic metastases; the liver tumor postoperative recurrence can be inhibited; popularization and use values are realized.

The invention relates to the technical field of biological medicines, firstly provides a folic acid modified Pluronic P85 copolymer and also relates to a preparation method of a 5-fluorouracil anti-cancer nano drug. Experiments show that the 5-fluorouracil nano drug prepared by adopting the folic acid modified Pluronic P85 copolymer can be used for obviously inhibiting tumour cell growth; meanwhile, in a mouse colonic carcinoma hepatic metastasis model, formation of colonic carcinoma liver metastases can be obviously reduced, and lifetime of a mouse can be obviously prolonged, so that the folic acid modified Pluronic P85 copolymer has a good effect on resisting colonic carcinoma hepatic metastasis, and the 5-fluorouracil anti-cancer nano drug is hopeful to be an anti-tumour drug with a clinical application prospect.

The invention relates to the technical field of colon cancer liver metastasis generation mechanism research, in particular to an establishment method of a novel liver fibroblast strain. Liver tumor related fibroblasts and normal liver fibroblasts from the same colon cancer liver metastasis patient are provided and used for researching the occurrence and development mechanism of liver metastasis of colon cancer, can pair each other, and can eliminate tissue heterogeneity caused by individual difference. The establishment method comprises the following steps that S1, a sterile culture medium is prepared; S2, tissues are separated; S3, the tissues are cleaned; S4, the tissues are treated; S5, the tissues are cultured; S6, a cell strain is identified; and S7, the cell strain is named. The establishment method of the novel liver fibroblast strain is high in objectivity, high in intuition, rapid and accurate, and a novel cell model can be provided for fundamental research on occurrence and progress of liver metastasis of the patient with the colon cancer.

The invention discloses application of RFPL1S-201 in the preparation of drugs for inhibiting the proliferation, invasion and / or metastasis of ovarian cancer, application of RFPL1S-201 or substances that promote the expression of RFPL1S-201 in the preparation of drugs for inhibiting the proliferation, invasion and / or metastasis of ovarian cancer, and application of expression plasmids overexpressing RFPL1S-201 in the preparation of drugs for inhibiting the proliferation, invasion and / or metastasis of ovarian cancer. It is found that lncRNA RFPL1S-201 can inhibit the proliferation, invasion andmetastasis of ovarian cancer cells, and meanwhile lncRNA RFPL1S-201 can inhibit the liver metastasis of ovarian cancer in vivo. A mechanism of action is mainly to inhibit tumor progression and promotetumor chemotherapy sensitivity by inhibiting an IFN-STAT1 signal channel.

The invention discloses an application of alkane compound pristane as an immunopotentiator in preparation of drugs for preventing and treating solid tumors. The invention finds for the first time thatthe natural compound alkane compound pristane can be used for preparing a systemic immunopotentiator, and finds the application of the systemic immunopotentiator in preparation of the drugs for preventing and treating solid tumors. The invention proves that the low-dose pristane can be used for effectively preventing breast tumors, inhibiting lung metastasis of the breast tumors, improving prognosis survival, effectively inhibiting liver metastasis and lung metastasis of melanoma, and increasing depilation-free survival rate. Research results show that enhancing the overall immunity is an effective strategy for preventing and treating solid tumors. In addition, the invention finds and proves that the alkane compound pristane can become a novel potential medicine for preventing and treating solid tumors.

The invention belongs to the technical field of medicine, and particularly discloses application of cGAMP in treatment of colorectal cancer hepatic metastases. Studies show that cGAMP can remarkably inhibit colorectal cancer from metastasizing to the liver, has an obvious antineoplastic function, and can be utilized for preparing anti-tumor metastasis medicine. A C57BL / 6 mouse colorectal cancer metastasis mold proves that cGAMP has a remarkable inhibition function on colorectal cancer cell strains MC38, tumor cells are prevented from metastasizing to the liver, and dendritic cells (DC cells) are activated, IL-2, IFN-gamma and IFN-beta expression relevant to immune response is improved, so that cGAMP can be utilized for treating colorectal cancer hepatic metastases.

The invention belongs to the technical field of medicines, and relates to an exosome membrane-coated cucurbitacin B and oxidation-responsive antitumor prodrug co-loaded bionic nanoparticle, and an application thereof in the preparation of drugs for treating tumor metastasis diseases. The nanoparticle can ablate primary tumors and target circulating tumor cells so as to inhibit tumor metastasis. The exosome membrane-coated co-loaded bionic nanoparticle comprises 1-2 wt% of cucurbitacin B, 6-8 wt% of an oxidation-responsive antitumor prodrug, 60-70 wt% of a nano-carrier material, and the balanceof an exosome membrane, and the weight ratio of the cucurbitacin B to the oxidation-responsive antitumor prodrug is 1:4 to 1:8. The exosome membrane-coated cucurbitacin B and oxidation-responsive antitumor prodrug co-loaded bionic nanoparticle has an obvious effect of treating tumor metastasis, especially lung or liver metastasis of breast cancer, and can be used for preparing antitumor drugs.

The invention belongs to the field of prognosis evaluation of metastatic kidney cancer patients, and particularly relates to a prediction model for survival benefit of metastatic kidney cancer patients after systematic treatment and an establishment method and application thereof. The prediction model for survival benefit of the metastatic kidney cancer patients after systematic treatment is a line chart model made by collecting time from primary diagnosis to systematic treatment of the metastatic kidney cancer patient, Karnofsky physical strength score, anemia, neutrophil polycythemia, thrombocythemia, hypercalcemia and bone / brain / liver metastasis, thereby predicting the time when the patient begins to receive system treatment to death. For a metastatic kidney cancer patient receiving systematic treatment, the actual condition of the influence variable in the column diagram can be scored, and the survival rate condition of the patient in the twelfth month and the twenty-fourth month can be obtained according to the corresponding position of the total column diagram, so that clinical doctors can use the survival rate in daily work more conveniently.

The invention belongs to the technical field of medicines, particularly relates to application of PLX3397 in treatment of colorectal cancer, and discloses novel application of PLX3397, namely application of PLX3397 in treatment of colorectal cancer. Research finds that oral administration of PLX3397 can significantly inhibit malignant proliferation of subcutaneous transplanted tumor of colorectal cancer, and also can significantly reduce liver metastasis of colorectal cancer, and the combination of PLX3397 and 5-FU can achieve a combined synergistic effect. The PLX3397 can be prepared into the medicine for treating the colorectal cancer, or the medicine for inhibiting the proliferation of the colorectal cancer cells, or the medicine for reducing the liver metastasis of the colorectal cancer cells. Meanwhile, the PLX3397 has low toxic and side effects when being used for treating the colorectal cancer, so that a new way and a new direction are provided for treatment of the colorectal cancer, and the PLX3397 has important application value.

The invention relates to the treatment of cancer. More particularly, the invention relates to the treatment of metastatic cancer. The invention provides new treatments for colon cancer patients who develop metastasis in the liver. The invention provides a method for treating hepatic metastatic colon cancer in a subject, the method comprising administering to the subject a small molecule selective inhibitor of CDK8 / 19 at a dosage that inhibits growth of the hepatic metastatic colon cancer, and does not cause a dose-limiting toxicity. The invention further provides a method for treating a subject having both a primary colon cancer tumor and hepatic metastatic colon cancer, the method comprising administering to the subject a small molecule selective inhibitor of CDK8 / 19 at a dosage that inhibits growth of the hepatic metastatic colon cancer, but does not significantly inhibit growth of the primary colon cancer tumor.

The invention belongs to the technical fields of medicament forms and preparation of nano medicaments, and relates to a triblock copolymer micelle and freeze-drying preparation loading taxane medicaments, and a preparation method and application thereof. In order to enable the micelle provided by the invention to be used clinically, the loading capacity, entrapment rate and stability of the preparation need to be guaranteed. The micelle is prepared from the following components in parts by weight: 1 part of taxane medicament and 1.5-99 parts of triblock copolymer polycaprolactone-polyethyleneglycol-polycaprolactone, wherein the molecular weight ratio of polycaprolactone to polyethylene glycol in the triblock copolymer is 0.5-3. The micelle or freeze-drying preparation loading taxane medicaments can be used for treating patients with cancer, tumors, Kaposi sarcoma, malignant tumors, tissue dysfunction or hyperplasia secondary to tissue damage and any other disease capable of reacting with the taxane medicaments, and has especially obvious curative effects on hepatoma, liver metastasis, ovarian cancer and breast cancer.

The invention provides a JAK1 gene g.[227149insA] mutation detection kit based on double-stranded DNA peptide ligase and a method thereof. The invention is characterized in that a target gene mutationfragment is directly captured and enriched before exponential amplification, and then the target gene mutation fragment is specifically amplified and detected. The JAK1 gene g.[227149insA] detectionkit mainly comprises dDPlaseI ligase, a dDPlaseI ligase buffer solution, RNase H enzyme, magnetic polypeptide Ps, an RNA primer Pr, a DNA primer Pn, a DNA fragment Pd and a DNA primer Pm, wherein theamino acid sequence of dDPlaseI ligase is as shown in SEQ ID NO: 1. The detection method mainly comprises the following four parts: pre-amplification, RNase H enzyme digestion, dDPlaseI enzyme connection and magnetic bead separation, and specific amplification. The detection kit and the detection method provided by the invention have the characteristics of strong specificity, accuracy, high efficiency, simplicity, convenience and economy, can effectively detect JAK1 gene g.[ 227149insA] mutation with the content as low as 1% in a sample, and can be applied to prediction and diagnosis and treatment of liver metastasis of middle-aged female colorectal cancer patients.